Research
Energy balance
Semaglutide has been approved by the FDA for the treatment of obesity or overweight.
Healthcare providers can prescribe semaglutide for weight management in eligible patients.
StrongSupportsmedium confidence
Recently, the US Food and Drug Administration (FDA) approved the use of semaglutide for patients with obesity or overweight.
Why this rating
Based on official FDA approval.
Source
Once‐weekly semaglutide for obesity or overweight: A systematic review and meta‐analysis
Ke He et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14612
Meta-analysisCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →